C10orf95 Inhibitors
Inhibitors of C10orf95 target the protein's activity through a multifaceted approach affecting various signaling pathways and biochemical processes. Some inhibitors work by hindering the activation of upstream tyrosine kinase receptors, thereby preventing the initiation of a series of phosphorylation events critical for C10orf95's functional role. Others impede crucial intracellular signaling cascades such as the PI3K/Akt pathway or the MAPK/ERK pathway, both of which may be fundamental to the protein's regulation and activity. By blocking these pathways, the inhibitors effectively reduce C10orf95 activity by preventing its post-translational modification or activation. Additionally, some compounds may alter the protein's activity through the modulation of cellular growth and metabolism, for example, by inhibiting mTOR signaling which could be central to the function of C10orf95 in growth regulation.
Moreover, specific inhibitors may act on cell cycle-related kinases that are involved with C10orf95's regulation, which would result in a decrease in its activity by preventing cell cycle progression signals from reaching the protein. Others might employ a strategy to stabilize proteins that naturally inhibit C10orf95, thus reducing its activity indirectly. This could involve the inhibition of proteasome-mediated degradation pathways, altering the cellular concentration of regulatory proteins. Additionally, inhibitors could target DNA repair mechanisms, which would lead to decreased activity through impaired DNA repair processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A non-selective protein kinase inhibitor that hinders C10orf95 function by broadly inhibiting phosphorylation processes necessary for its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinase (PI3K) inhibitor which may impede signaling pathways downstream of C10orf95 that rely on PI3K activity, thereby reducing C10orf95's functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of mitogen-activated protein kinase kinase (MEK), which could impede the MEK/ERK pathway. Given C10orf95 is involved in this pathway, this compound would reduce its activity by preventing pathway progression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAP kinase inhibitor that may disrupt the p38 MAPK signaling pathway. Assuming C10orf95 operates within this pathway, the inhibition of p38 MAPK would result in reduced activity of C10orf95. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor which may decrease the functional activity of C10orf95 given it is involved in the mTOR signaling pathway by hindering downstream effects such as protein synthesis. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that could lead to the accumulation of ubiquitinated proteins, affecting protein degradation pathways in which C10orf95 may be involved, hence reducing its functional presence. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
An inhibitor of ADP-ribosylation factor (ARF), which could disrupt Golgi apparatus function. Assuming C10orf95 relies on Golgi-mediated processes, Brefeldin A would reduce its functional activity by impairing Golgi function. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
An immunosuppressant that inhibits calcineurin, potentially affecting signaling pathways that involve C10orf95, thus reducing its activity assuming it is involved in calcium-dependent signaling processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A c-Jun N-terminal kinase (JNK) inhibitor that may impede JNK signaling pathways. Assuming C10orf95's activity is JNK-dependent, inhibition of JNK by SP600125 would reduce its functional activity. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
A calmodulin antagonist which may inhibit calcium/calmodulin-dependent processes. Assuming C10orf95's function is regulated by calmodulin, W-7 would lead to reduced activity of C10orf95 by inhibiting its regulator. | ||||||